Shares of Epizyme Inc. (NASDAQ:EPZM) traded down 6.2% on Friday . The company traded as low as $8.12 and last traded at $8.16, with a volume of 322,837 shares changing hands. The stock had previously closed at $8.70.

A number of analysts recently weighed in on the stock. Leerink Swann reissued an “outperform” rating and issued a $39.00 price target on shares of Epizyme in a report on Tuesday, June 21st. Zacks Investment Research raised shares of Epizyme from a “sell” rating to a “hold” rating in a report on Wednesday, August 10th. JMP Securities reissued a “buy” rating and issued a $28.00 price target on shares of Epizyme in a report on Thursday, June 23rd. Wedbush reissued an “outperform” rating and issued a $22.00 price target on shares of Epizyme in a report on Monday, May 9th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $26.00 price target on shares of Epizyme in a report on Monday, June 20th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $23.11.

The firm has a 50-day moving average price of $9.67 and a 200 day moving average price of $10.41. The stock’s market cap is $472.92 million.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.03. Equities analysts anticipate that Epizyme Inc. will post ($2.19) EPS for the current year.

In other news, insider Robert A. Copeland sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $10.37, for a total transaction of $41,480.00. Following the completion of the sale, the insider now owns 35,538 shares of the company’s stock, valued at approximately $368,529.06. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

A hedge fund recently raised its stake in Epizyme stock. Jennison Associates LLC boosted its position in Epizyme Inc. (NASDAQ:EPZM) by 252.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 893,913 shares of the biopharmaceutical company’s stock after buying an additional 640,245 shares during the period. Jennison Associates LLC owned approximately 2.14% of Epizyme worth $14,320,000 as of its most recent filing with the SEC.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.